A stratified survival analysis further revealed that while FXYD5 expression had no significant prognostic value in early-stage (I/II) HCC, high FXYD5 expression was significantly correlated with poor overall survival in late-stage (III/IV) patients (Supplementary Fig. 1f). This evidence concerns the gene FXYD5 and hepatocellular carcinoma.